ALK and non-small cell lung carcinoma: Given the long natural history and younger age at diagnosis of ALK+ tumors, and enhanced intracranial activity of newer ALK TKIs, the question of whether ALK+ NSCLC BM can be initially managed with ALK TKIs while deferring upfront RT is pertinent.